Citadel Advisors’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-3,800
| Closed | -$450K | – | 15026 |
|
|
2021
Q1 | $450K | Sell |
3,800
-2,000
| -34% | -$237K | ﹤0.01% | 9910 |
|
|
2020
Q4 | $685K | Sell |
5,800
-6,100
| -51% | -$708K | ﹤0.01% | 7549 |
|
|
2020
Q3 | $1.32M | Buy |
11,900
+1,100
| +10% | +$118K | ﹤0.01% | 5518 |
|
|
2020
Q2 | $1.1M | Buy |
10,800
+6,200
| +135% | +$663K | ﹤0.01% | 5661 |
|
|
2020
Q1 | $496K | Sell |
4,600
-4,400
| -49% | -$506K | ﹤0.01% | 6472 |
|
|
2019
Q4 | $1.05M | Sell |
9,000
-7,400
| -45% | -$857K | ﹤0.01% | 5501 |
|
|
2019
Q3 | $1.88M | Buy |
16,400
+9,100
| +125% | +$905K | ﹤0.01% | 4574 |
|
|
2019
Q2 | $696K | Sell |
7,300
-600
| -8% | -$56.5K | ﹤0.01% | 6291 |
|
|
2019
Q1 | $721K | Buy |
7,900
+2,500
| +46% | +$205K | ﹤0.01% | 6166 |
|
|
2018
Q4 | $410K | Sell |
5,400
-14,900
| -73% | -$1.1M | ﹤0.01% | 6724 |
|
|
2018
Q3 | $1.62M | Sell |
20,300
-100
| -0.5% | -$9.32K | ﹤0.01% | 4746 |
|
|
2018
Q2 | $2.03M | Buy |
20,400
+15,600
| +325% | +$1.35M | ﹤0.01% | 4091 |
|
|
2018
Q1 | $389K | Buy |
+4,800
| New | +$388K | ﹤0.01% | 6317 |
|
|
2017
Q2 | – | Sell |
-4,100
| Closed | -$411K | – | 8512 |
|
|
2017
Q1 | $411K | Sell |
4,100
-3,800
| -48% | -$406K | ﹤0.01% | 5359 |
|
|
2016
Q4 | $849K | Buy |
7,900
+1,800
| +30% | +$210K | ﹤0.01% | 4081 |
|
|
2016
Q3 | $759K | Buy |
+6,100
| New | +$720K | ﹤0.01% | 4207 |
|
Citadel Advisors's CBPO Position: Q2 2021 in Review
Citadel Advisors sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 318,196 shares — an estimated $37.7M sold.
Citadel Advisors first reported a position in CBPO in Q1 2014 and held it in 21 quarters. The position peaked at $37.7M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Citadel Advisors reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Citadel Advisors sold 318,196 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $37.7M.
- Citadel Advisors first reported a position in China Biologic Products Holdings, Inc. in Q1 2014 and held it in 21 quarters.
- Citadel Advisors's China Biologic Products Holdings, Inc. position peaked at $37.7M in Q1 2021.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.